San Diego-based Viking Therapeutics marked alone as a significant competitor from the weight loss drug industry in February soon after revealing promising information from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in March the compa